Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure

Advanced Epithelial Ovarian Cancer (EOC) patients frequently relapse by 24 months and develop resistant disease. Research on EOC therapies relies on cancer cell lines established decades ago making Patient Derived Xenografts (PDX) attractive models, because they are faithful representations of the o...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Pierre-Emmanuel, du Manoir, Stanislas, Orsetti, Béatrice, Bras-Gonçalves, Rui, Lambros, Mario B., MacKay, Alan, Nguyen, Tien-Tuan, Boissiére, Florence, Pourquier, Didier, Bibeau, Frédéric, Reis-Filho, Jorge S., Theillet, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695063/
https://www.ncbi.nlm.nih.gov/pubmed/26334103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695063/
https://www.ncbi.nlm.nih.gov/pubmed/26334103

Ejemplares similares